The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required.

Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Steatohepatitis

Obesity

Diabetes Mellitus, Type 2

The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required

Spartz Balloon

Asian Institute of Gastroenterology Hospital

Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease

A Clinical Study on the Effect of Adjustable Intragastric Balloon in Obese Patients With Non Alcoholic Fatty Liver Disease(NAFLD) or Non-Alcoholic Steatohepatitis (NASH) With or Without Diabetes Mellitus

The 'NAFLD activity score' (NAS) is the most widely used histological grading and staging system for NAFLD. It is a histological scoring system addressing the full spectrum of NAFLD. It includes steatosis, hepatocellular ballooning, lobular inflammation, fibrosis, and the absence of lipogranulomas. In our study, liver histology was assessed by a single pathologist before and after treatment.
Steatosis is graded as 0, 1, 2 and 3 depending on steatosis in hepatocytes.Lobular inflammation is graded as 0,1,2 and 3 depending on number of foci of inflammation per 20x field. Hepatocellular ballooning is graded as 0,1 and 2 depending on amount of ballooning. Fibrosis is graded as 0,1,2,3 and 4 depending on level of fibrosis. A composite score is calculated by addition on individual scores from steatosis, hepatocellular ballooning, lobular inflammation and fibrosis.

Percentage of total body weight loss (%TBWL) will be calculated as 6 months after removal of balloon.

Liver enzymes are non-invasive markers of liver injury. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) change will be studied in comparison with baseline levels

Total number of patients achieving more than 25% Excess weight loss at 6 months will be studied.

Changes in glycemic control will be assessed by change in HbA1c after 6 months of balloon removal will be assessed.

Rakesh K

Consultant Gastroenterologist

Asian Institute of Gastroenterology, India

The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year which have capability for decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required

hepatolenticular degeneration/obesity

Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease

Baz done ki pi konplè remèd fèy medsin te apiye nan syans